The most commonly reported side effects of ixekizumab include injection site pain, psoriasis, and injection site erythema, based on 35,924 FDA adverse event reports from 2016 to 2025. 8.8% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for ixekizumab.
These are voluntary reports and do not establish that ixekizumab caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside ixekizumab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
55.6% of ixekizumab adverse event reports involve female patients and 35.6% involve male patients. The largest age group is adult at 81%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking ixekizumab when the adverse event was reported.
Showing 15 of 217 indications
Ixekizumab is sold under the brand name Taltz.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.